Residency · Residency · Geriatrics

Vascular and Lewy Body Dementias

Introduction

Vascular dementia and dementia with Lewy bodies represent the second and third most common causes of dementia respectively, following Alzheimer disease. Vascular dementia accounts for approximately 15 to 20 percent of dementia cases at autopsy, while dementia with Lewy bodies accounts for 5 to 15 percent. These prevalence figures, however, understate the true contribution of these pathologies to the burden of dementia in elderly populations because mixed pathology is the rule rather than the exception. Pure forms of any single dementia are less common than overlapping pathological processes, and accurate differentiation among dementia subtypes has critical management implications, particularly regarding antipsychotic use in dementia with Lewy bodies, where neuroleptic sensitivity can be life-threatening.

Vascular Dementia

Pathology and Subtypes

Vascular dementia encompasses a heterogeneous group of cognitive disorders caused by cerebrovascular disease, with several distinct pathological subtypes that differ in their clinical presentation and course.

Multi-infarct dementia results from multiple cortical or cortico-subcortical infarcts occurring in different vascular territories, producing a stepwise pattern of cognitive decline in which each new infarct adds an increment of deficit. Strategic infarct dementia, by contrast, results from a single infarct in a critical location such as the thalamus, angular gyrus, caudate nucleus, or hippocampus, where even a small lesion can produce disproportionate cognitive impairment due to the strategic importance of the affected structure in cognitive circuitry.

Subcortical ischemic vascular dementia is the most common form and results from extensive white matter disease (leukoaraiosis) and lacunar infarcts affecting subcortical circuits that connect frontal cortical regions with basal ganglia and thalamic structures. The clinical phenotype is characterized by executive dysfunction, reduced processing speed, gait disturbance, and urinary symptoms, reflecting disruption of frontal-subcortical loops.

Post-stroke dementia describes cognitive impairment developing within six months of a clinically apparent stroke, with an incidence of 20 to 30 percent at three months post-stroke. Cerebral amyloid angiopathy, caused by deposition of amyloid-beta in cerebral vessel walls, produces recurrent lobar hemorrhages, white matter changes, and progressive cognitive decline. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), caused by mutations in the NOTCH3 gene, is an inherited form of vascular dementia characterized by young-onset migraine with aura, recurrent subcortical strokes, progressive dementia, and mood disturbances.

Clinical Features

The hallmark cognitive deficit of vascular dementia is executive dysfunction, manifesting as impaired planning, set-shifting, working memory, and judgment. Processing speed reduction is characteristically disproportionate to memory impairment, which helps distinguish vascular dementia from Alzheimer disease at the bedside. When memory impairment does occur, it typically follows a retrieval deficit pattern in which performance improves with cueing, in contrast to the encoding deficit seen in Alzheimer disease where cueing provides no benefit because the information was never effectively stored.

Gait disturbance is a common and characteristic feature, presenting as a frontal or magnetic gait with small steps, a wide base, and difficulty initiating walking. Emotional lability, also known as pseudobulbar affect, produces episodes of involuntary crying or laughing that are disproportionate to the underlying emotional state. Depression is a frequent comorbidity, present in 30 to 50 percent of patients. Focal neurological signs including hemiparesis, visual field deficits, and dysarthria may be present depending on the locations of vascular lesions. The clinical course may follow a stepwise pattern (in multi-infarct dementia) or may progress insidiously (in subcortical ischemic vascular dementia).

Diagnostic Criteria

The NINDS-AIREN criteria have traditionally been used for diagnosing vascular dementia, requiring the presence of dementia, cerebrovascular disease documented by both clinical examination and neuroimaging, and a temporal relationship between the two. The VASCOG criteria, published in 2014, provide an updated and more inclusive framework that requires cognitive impairment combined with imaging evidence of cerebrovascular disease.

Key neuroimaging findings on MRI include lacunar infarcts, extensive white matter hyperintensities, and strategic infarcts. The Fazekas scale provides a standardized grading system for white matter hyperintensities:

The scale ranges from grade 0 (absent) through grade 1 (punctate foci) and grade 2 (early confluent lesions) to grade 3 (confluent lesions extending to the subcortical cortex). A minimum threshold of approximately 25 percent of white matter involvement or a strategic infarct location is generally required to attribute cognitive impairment to vascular disease.

Management of Vascular Dementia

The primary management strategy for vascular dementia is aggressive secondary prevention of cerebrovascular disease to prevent further vascular injury. This encompasses hypertension management targeting less than 130/80 mmHg per SPRINT guidelines (though evidence in patients with established dementia is weaker than in cognitively normal populations), diabetes management targeting a hemoglobin A1c below 8 percent in elderly patients with dementia (with a critical emphasis on avoiding hypoglycemia), hyperlipidemia management with statin therapy for secondary prevention, antiplatelet therapy with aspirin 81 mg or clopidogrel 75 mg for atherosclerotic disease, anticoagulation for atrial fibrillation with direct oral anticoagulants preferred over warfarin, smoking cessation, regular exercise, and adherence to a Mediterranean diet.

Cholinesterase inhibitors are not FDA-approved for vascular dementia, but modest evidence supports their benefit. The Donepezil 307 and 308 trials demonstrated ADAS-cog improvements of 1.7 to 2.0 points versus placebo, and a trial of donepezil should be considered, especially when mixed Alzheimer disease and vascular pathology is suspected. Memantine has minimal evidence in pure vascular dementia but may be considered if mixed pathology is present. Depression should be treated aggressively, with SSRIs as the preferred first-line agents and duloxetine or venlafaxine as alternatives. Pseudobulbar affect, when functionally limiting, can be treated with dextromethorphan/quinidine (Nuedexta) at 20/10 mg twice daily.

<image>A brain MRI comparison panel showing vascular dementia subtypes. Display four axial brain MRI images (T2 FLAIR sequences) side by side: (1) Multi-infarct dementia showing multiple cortical and subcortical infarcts of varying ages in different vascular territories; (2) Strategic infarct showing a single left thalamic lacunar infarct with annotation explaining its disproportionate cognitive impact; (3) Subcortical ischemic vascular dementia showing extensive confluent periventricular and deep white matter hyperintensities (Fazekas grade 3) with multiple lacunar infarcts in the basal ganglia; (4) Cerebral amyloid angiopathy showing a GRE/SWI sequence with multiple cortical microbleeds in a lobar distribution. Label each image clearly and include the Fazekas grading scale as a reference panel below.</image>

Dementia with Lewy Bodies

Pathology

Dementia with Lewy bodies is characterized by the accumulation of alpha-synuclein aggregates forming Lewy bodies (intracytoplasmic inclusions) and Lewy neurites within neurons. The distribution of Lewy body pathology follows an ascending pattern from the brainstem through limbic structures to the neocortex. There is significant pathological overlap with Parkinson disease dementia, as both conditions share the same underlying alpha-synuclein pathology but differ in their temporal relationship between cognitive and motor symptoms. In dementia with Lewy bodies, cognitive symptoms precede or occur within one year of parkinsonism, whereas in Parkinson disease dementia, parkinsonism precedes dementia by more than one year, a distinction codified as the "one-year rule."

The overlap extends to Alzheimer disease pathology as well, with 50 to 80 percent of dementia with Lewy bodies cases also harboring significant Alzheimer disease co-pathology in the form of amyloid plaques and neurofibrillary tangles. A critically important pathological feature is that the cholinergic deficit in dementia with Lewy bodies is even more severe than in Alzheimer disease, which explains the characteristically robust response to cholinesterase inhibitors observed in this condition.

Clinical Features — The Four Core Features

The revised consensus criteria identify four core clinical features of dementia with Lewy bodies, any combination of which significantly strengthens the clinical diagnosis.

Fluctuating cognition is characterized by spontaneous variations in attention and alertness that may be dramatic, with episodes of staring, drowsiness, or unresponsiveness lasting minutes to hours, interspersed with periods of near-normal cognitive function. Caregivers often describe "good days and bad days" that are far more variable than the relatively stable day-to-day function seen in Alzheimer disease. These fluctuations can be assessed using the Mayo Fluctuations Composite Scale or the Clinician Assessment of Fluctuation.

Recurrent visual hallucinations are typically well-formed, detailed, and often depict people, children, or animals. They are present in 60 to 80 percent of patients and are often nonthreatening initially, though they may become distressing as the disease progresses. Hallucinations tend to be worse in dim lighting, and insight into their unreality may be preserved early in the disease course, distinguishing them from the less formed and typically later-appearing hallucinations that can occur in advanced Alzheimer disease.

REM sleep behavior disorder involves the loss of normal REM sleep atonia, resulting in dream enactment behavior that may include punching, kicking, yelling, or falling out of bed during sleep. This feature is of particular diagnostic importance because it may precede cognitive symptoms by years to decades, serving as a prodromal marker for synucleinopathy. Confirmation requires polysomnography demonstrating REM sleep without atonia.

Parkinsonism in dementia with Lewy bodies manifests as bradykinesia, rigidity, and postural instability, though rest tremor is less common than in idiopathic Parkinson disease. The onset tends to be more symmetric than in Parkinson disease, with axial predominance and early gait impairment.

Supportive and Indicative Biomarkers

Indicative biomarkers strongly support the diagnosis of dementia with Lewy bodies. Reduced dopamine transporter uptake on DaT-SPECT (using FP-CIT) or F-DOPA PET demonstrates nigrostriatal dopaminergic degeneration with a sensitivity of 78 percent and specificity of 90 percent and is the single most useful biomarker for distinguishing dementia with Lewy bodies from Alzheimer disease. Polysomnography-confirmed REM sleep behavior disorder provides strong supportive evidence. Reduced cardiac MIBG uptake reflects postganglionic sympathetic denervation, which is characteristic of Lewy body disease.

Supportive biomarkers include preserved medial temporal lobe volumes on MRI (in contrast to the hippocampal atrophy characteristic of Alzheimer disease), occipital hypoperfusion or hypometabolism on FDG-PET or SPECT with the cingulate island sign, and prominent posterior slow-wave activity with periodic fluctuations on EEG.

Revised DLB Consortium Criteria (McKeith et al., 2017)

The fourth consensus report of the DLB Consortium establishes diagnostic criteria based on clinical features and biomarkers. Probable dementia with Lewy bodies requires dementia plus two or more core clinical features, or one core feature plus one or more indicative biomarkers. Possible dementia with Lewy bodies requires dementia plus one core feature, or one or more indicative biomarkers alone. The cognitive profile characteristically features prominent early deficits in attention, executive function, and visuospatial abilities, in contrast to the memory-predominant presentation of Alzheimer disease.

<image>A clinical features comparison chart between Dementia with Lewy Bodies and Alzheimer Disease. Create a two-column comparison table with visual icons for each feature. Left column DLB, right column AD. Compare: onset pattern (fluctuating vs. insidious), predominant cognitive domain (attention/executive/visuospatial vs. memory), hallucinations (early, well-formed visual vs. late, if present), parkinsonism (early, common vs. late, uncommon), REM sleep behavior disorder (characteristic vs. uncommon), neuroleptic sensitivity (severe vs. moderate), autonomic dysfunction (prominent orthostasis, constipation vs. less prominent), medial temporal atrophy on MRI (preserved vs. atrophied), DaT scan (abnormal vs. normal), cholinesterase inhibitor response (robust vs. moderate). Use color coding to highlight key differentiating features. Include a Venn diagram at the bottom showing the overlap zone of mixed AD/DLB pathology.</image>

Management of DLB

Cognitive Symptoms

Cholinesterase inhibitors are the first-line treatment for cognitive symptoms in dementia with Lewy bodies and produce a more robust response than in Alzheimer disease, reflecting the more severe cholinergic deficit. Rivastigmine has the strongest evidence base, with the landmark study by McKeith and colleagues in 2000 demonstrating significant improvement in attention, delusions, and hallucinations. Donepezil is also effective. Cholinesterase inhibitors in dementia with Lewy bodies have the notable advantage of improving both cognition and neuropsychiatric symptoms simultaneously. Treatment should be initiated at low doses with slow titration, and monitoring for worsening parkinsonism (a rare complication) is advisable.

Visual Hallucinations and Psychosis

The management of psychosis in dementia with Lewy bodies demands extreme caution because of the severe neuroleptic sensitivity that affects 30 to 50 percent of patients. Typical antipsychotics, particularly haloperidol, must be absolutely avoided, as they can precipitate severe rigidity, obtundation, autonomic instability, and neuroleptic malignant syndrome-like reactions, with a two- to three-fold increase in mortality. Most atypical antipsychotics, including olanzapine and risperidone, also carry significant risk.

Non-pharmacological approaches should always be attempted first, including optimizing lighting (hallucinations worsen in dim environments), providing reassurance, redirecting attention, and correcting sensory deficits. When pharmacotherapy is needed, quetiapine at 12.5 to 50 mg at bedtime carries the least dopamine D2 blockade among atypical antipsychotics and has the most favorable safety profile, though evidence for efficacy is modest. Pimavanserin, a 5-HT2A inverse agonist with no D2 receptor activity, is FDA-approved for Parkinson disease psychosis at a dose of 34 mg daily and has demonstrated benefit in the HARMONY trial for dementia-related psychosis. Clozapine is effective for refractory cases but requires regular complete blood count monitoring for agranulocytosis, limiting its practical utility.

Parkinsonism

Levodopa/carbidopa may provide modest motor benefit in dementia with Lewy bodies but is generally less effective than in idiopathic Parkinson disease. Treatment should be initiated at low doses, such as carbidopa-levodopa 25/100 half-tablet twice daily, with cautious titration, as levodopa can exacerbate hallucinations and psychosis. Anticholinergic medications (trihexyphenidyl, benztropine) are contraindicated due to their deleterious effects on cognition. Amantadine should also be avoided as it may worsen hallucinations. Physical therapy focusing on gait training, balance exercises, and fall prevention is an essential component of motor symptom management.

REM Sleep Behavior Disorder

Melatonin at doses of 3 to 12 mg at bedtime is the first-line treatment for REM sleep behavior disorder due to its favorable safety profile, and it is effective in reducing dream enactment behaviors in the majority of patients. Clonazepam at 0.25 to 0.5 mg at bedtime is also effective but carries significant risks of sedation, falls, and respiratory depression in elderly patients. Environmental safety measures are essential regardless of pharmacotherapy and include padded bed rails, removal of sharp objects from the bedroom, and consideration of sleeping arrangements that protect the bed partner from injury.

Autonomic Dysfunction

Autonomic dysfunction is a prominent feature of dementia with Lewy bodies and requires systematic management. Orthostatic hypotension is addressed through a stepwise approach beginning with non-pharmacological measures (adequate hydration, compression stockings) and escalating to pharmacotherapy with midodrine 2.5 to 10 mg three times daily, droxidopa 100 to 600 mg three times daily, or fludrocortisone 0.1 to 0.2 mg daily as needed. Constipation is managed with fiber and osmotic laxatives, avoiding chronic use of stimulant laxatives. Urinary dysfunction should be addressed with behavioral strategies first, and anticholinergic bladder medications such as oxybutynin must be avoided due to their cognitive effects.

<image>A management algorithm for Dementia with Lewy Bodies organized by symptom domain. Create a central box labeled "DLB Management" with four radiating branches: (1) Cognitive — showing cholinesterase inhibitors as first-line with dosing details; (2) Neuropsychiatric — showing a traffic light system with RED (avoid: haloperidol, olanzapine, risperidone), YELLOW (caution: quetiapine with dosing), GREEN (preferred: pimavanserin, non-pharmacological approaches); (3) Motor — showing levodopa with cautions and physical therapy; (4) Sleep/Autonomic — showing melatonin for RBD, orthostatic hypotension management ladder. Include a prominent warning box at the top stating "NEUROLEPTIC SENSITIVITY: Avoid typical antipsychotics — 30-50% risk of severe adverse reaction including death."</image>

Differentiating DLB, PDD, and AD

The Lewy Body Spectrum

Dementia with Lewy bodies and Parkinson disease dementia exist on a spectrum of Lewy body disease, sharing the same underlying alpha-synuclein pathology and differing primarily in the temporal sequence of cognitive and motor symptom onset. The clinical distinction based on the one-year rule is admittedly somewhat arbitrary but retains practical utility for treatment planning and prognostication. Both conditions respond to cholinesterase inhibitors, and both carry the risk of neuroleptic sensitivity, underscoring their shared pathological substrate.

Key Differentiators from AD

Several clinical features reliably distinguish dementia with Lewy bodies from Alzheimer disease. Fluctuating attention in dementia with Lewy bodies contrasts with the relatively stable day-to-day function in early Alzheimer disease. Well-formed visual hallucinations appear early in dementia with Lewy bodies but are typically late or absent in Alzheimer disease. Parkinsonism is present early in dementia with Lewy bodies but is absent until the advanced stages of Alzheimer disease. Visuospatial and executive deficits predominate in dementia with Lewy bodies, whereas amnestic deficits predominate in Alzheimer disease. REM sleep behavior disorder is highly specific for synucleinopathy (dementia with Lewy bodies, Parkinson disease dementia, and multiple system atrophy) and is absent in Alzheimer disease. On MRI, hippocampal volume is characteristically preserved in dementia with Lewy bodies but atrophied in Alzheimer disease. The DaT scan is abnormal in dementia with Lewy bodies and normal in Alzheimer disease, making it the most useful differentiating biomarker between the two conditions.

Key Clinical Pearls

• Mixed vascular + Alzheimer pathology is the most common finding at autopsy in demented elderly — always consider dual pathology
• In vascular dementia, aggressive secondary prevention of cerebrovascular disease is the primary treatment strategy — there is no disease-specific cognitive pharmacotherapy
• Neuroleptic sensitivity in DLB is life-threatening — NEVER use haloperidol; quetiapine and pimavanserin are the safest pharmacological options
• REM sleep behavior disorder may precede DLB by decades — it is the strongest prodromal marker for synucleinopathy
• DaT-SPECT is the single most useful biomarker for distinguishing DLB from AD (sensitivity 78%, specificity 90%)
• Cholinesterase inhibitors (especially rivastigmine) are more effective in DLB than in AD — the cholinergic deficit is more severe
• When a patient with "Alzheimer disease" has prominent fluctuations, visual hallucinations, or falls early in the course — reconsider the diagnosis; it may be DLB

References

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
2. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218.
3. McKeith IG, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036.
4. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698-1706.
5. Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157-169.

Read this lecture as Markdown